Get the Stockscreener App
1.1356
1.25%
-0.0144
After Hours:
1.10
-0.0356
-3.13%
Okyo Pharma Limited stock is traded at $1.1356, with a volume of 16,628.
It is down -1.25% in the last 24 hours and up +1.39% over the past month.
OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions for various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chronic Pain, and Ocular Pain.
See More
Previous Close:
$1.15
Open:
$1.1008
24h Volume:
16,628
Relative Volume:
0.14
Market Cap:
$38.54M
Revenue:
-
Net Income/Loss:
$-13.27M
P/E Ratio:
-6.9244
EPS:
-0.164
Net Cash Flow:
$-7.70M
1W Performance:
+3.24%
1M Performance:
+1.39%
6M Performance:
+13.56%
1Y Performance:
-13.97%
1-Day Range:
$1.10
$1.15
1-Week Range:
$1.02
$1.18
52-Week Range:
$0.8075
$1.90
Okyo Pharma Limited Stock (OKYO) Company Profile
Compare OKYO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OKYO
Okyo Pharma Limited
|
1.1356 | 38.54M | 0 | -13.27M | -7.70M | -0.164 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.16 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.07 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
657.97 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
278.25 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
119.94 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Okyo Pharma Limited Stock (OKYO) Latest News
OKYO Pharma Announces Chairman and CEO Acquire Shares -February 03, 2025 at 09:04 am EST - Marketscreener.com
OKYO Pharma Announces Chairman and CEO Acquire Shares -January 31, 2025 at 07:00 am EST - Marketscreener.com
OKYO Pharma has dry eyes as a lucrative prize in its sights - Proactive Investors UK
OKYO Pharma insiders buy shares amid clinical trials - MSN
OKYO Pharma insiders acquire shares - Proactive Investors USA
OKYO Pharma insiders buy shares amid clinical trials By Investing.com - Investing.com South Africa
OKYO Pharma poised for multi-billion-dollar opportunity in ocular treatment market, analysts believe - Proactive financial news
OKYO Pharma Executives Increase Shareholdings, Affirming Market Confidence - TipRanks
OKYO Pharma Announces Chairman and CEO Acquire Shares - The Manila Times
OKYO Pharma advances neuropathic corneal pain drug trial - MSN
OKYO Pharma to Complete Enrollment of Neuropathic Corneal Pain Trial by End of Second Quarter - GlobeNewswire
OKYO Pharma Advances Clinical Trials with Encouraging Interim Results - TipRanks
OKYO Pharma advances neuropathic corneal pain drug trial By Investing.com - Investing.com Australia
OKYO Pharma nears full enrollment for neuropathic corneal pain trial with results expected by year-end - Proactive Investors UK
OKYO Pharma nears full enrollment for neuropathic corneal pain trial - Proactive Investors USA
MUSQ Global Music Industry ETF and OKYO Pharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - ACCESS Newswire
OKYO Pharma secures $1.4 million in non-dilutive funding - MSN
OKYO Pharma secures $1.4 million non-dilutive funding - MSN
Okyo Pharma receives $1.4M in non-dilutive financing - Yahoo Finance
OKYO Pharma (NASDAQ:OKYO) Shares Down 0.4% – What’s Next? - Defense World
OKYO Pharma secures $1.4 million non-dilutive funding By Investing.com - Investing.com Australia
OKYO Pharma secures non-dilutive funding to advance clinical programs - Proactive Investors UK
OKYO Pharma receives $1.4 million in non-dilutive funding, stock up - MSN
OKYO Pharma Secures $1.4 Million to Boost Ophthalmic Innovations - TipRanks
OKYO Pharma Receives $1.4 Million in Non-Dilutive Funding - The Manila Times
OKYO Pharma secures $1.4 million in non-dilutive funding By Investing.com - Investing.com South Africa
OKYO Pharma Secures $1.4M Non-Dilutive Funding for Breakthrough Eye Pain Treatment - StockTitan
Neuropathic Ocular Pain Market Is Booming Worldwide 2025-2032 | - openPR
OKYO Pharma Limited ("OKYO" or the "Company")Conversion of CLNs, cashless exercise of Warrants, and issue of equity - Marketscreener.com
OKYO Pharma (NASDAQ:OKYO) & Adaptimmune Therapeutics (NASDAQ:ADAP) Head-To-Head Review - Defense World
OKYO Pharma (NASDAQ:OKYO) Stock Price Up 1.7% – Should You Buy? - Defense World
OKYO Pharma : Results of AGM 2024 - Marketscreener.com
Contrasting Genocea Biosciences (NASDAQ:GNCA) and OKYO Pharma (NASDAQ:OKYO) - Defense World
Critical Comparison: OKYO Pharma (NASDAQ:OKYO) versus enGene (NASDAQ:ENGN) - Defense World
OKYO Pharma (NASDAQ:OKYO) Trading Down 1% – What’s Next? - Defense World
OKYO Pharma to join BTIG Ophthalmology Day By Investing.com - Investing.com Canada
OKYO Pharma to Participate at the 4th Annual BTIG Ophthalmology Conference - GlobeNewswire
OKYO Pharma to join BTIG Ophthalmology Day - Investing.com
OKYO Pharma to Highlight Innovations at BTIG Conference - TipRanks
OKYO Pharma CEO to present at BTIG Ophthalmology Day - Proactive Investors USA
Okyo Pharma Limited Stock (OKYO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):